Medtronic Plc

NYSE:MDT   3:59:59 PM EDT
-1.50 (-1.17%)

Medtronic Receives FDA Approval To Launch Clinical Study For Implantable Tibial Neuromodulation Therapy For Bladder Incontinence

Published: 04/27/2021 12:52 GMT
Medtronic Plc (MDT) - Medtronic Receives FDA Approval to Launch Clinical Study for Implantable Tibial Neuromodulation Therapy for Bladder Incontinence.
Medtronic Plc - New Investigational Device Aims to Expand Access to Therapy for Patients With Incontinence.
Medtronic Plc - As Part of Trial, Twenty Patients From Eight Sites in U.S. Will Receive a Device and Will Be Followed for 12 Months.
Medtronic Plc - Enrollment is Anticipated to Begin in May 2021.